SCHEMBL420201

SCHEMBL420201

CSCCS(C)(=O)=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14537520 0.82
SCHEMBL679862 0.78 NLRP3 (0.39)
SCHEMBL12456989 0.78 NLRP3 (0.39)
SCHEMBL7112088 0.77
SCHEMBL5784859 0.73
SCHEMBL12854170 0.73
SCHEMBL3511747 0.73
SCHEMBL10771596 0.73
SCHEMBL84504 0.73
SCHEMBL597046 0.71 NLRP3 (0.50)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230322996-A1 POLYMER-INTERACTION MOLECULE CONJUGATES AND METHODS OF USE LIFE TECHNOLOGIES AS (NO) 2023-10-12 US disclosed
US-11673100-B2 Systems and methods for integrated solar photodialysis THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-06-13 US disclosed
EP-3154997-B9 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2021-04-14 EP disclosed
EP-3753578-A1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF Novartis AG (CH) 2020-12-23 EP disclosed
EP-3154997-B1 AURISTATIN DERIVATIVES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2020-02-19 EP disclosed
US-10449739-B2 Hydrogel contact lenses with lubricious coating thereon NOVARTIS AG (CH) 2019-10-22 US disclosed
EP-3082877-B1 CYTOTOXIC PEPTIDES AND CONJUGATES THEREOF NOVARTIS AG (CH) 2019-08-28 EP disclosed
US-10016510-B2 Immunogenic composition in emulsion form Commissariat à l'énergie atomique et aux énergies alternatives (FR) 2018-07-10 US disclosed
US-9968673-B2 Immunogenic composition in emulsion form comprising two dispersed phases, one comprising an antigen and the other comprising an immunostimulating agent Commissariat á l'ènergie atomique et aux ènergies alternatives (FR) 2018-05-15 US disclosed
US-20180079158-A1 HYDROGEL CONTACT LENSES WITH LUBRICIOUS COATING THEREON ALCON INC. (CH) 2018-03-22 US disclosed
US-20100069571-A1 Thioester-Terminated Water Soluble Polymers and Method of Modifying the N-Terminus of a Polypeptide Therewith NEKTAR THERAPEUTICS (US) 2010-03-18 US disclosed
US-7511095-B2 Thioester-terminated water soluble polymers and method of modifying the N-terminus of a polypeptide therewith NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-03-31 US disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 US disclosed
US-20080318917-A1 POLYETHYLENE GLYCOLATED SUPEROXIDE DISMUTASE MIMETICS GALERA THERAPEUTICS, LLC 2008-12-25 US disclosed
US-20080166362-A1 New effector conjugates, process for their production and their pharmaceutical use BERGER MARKUS 2008-07-10 US disclosed
US-20080166362-A1 New effector conjugates, process for their production and their pharmaceutical use BERGER MARKUS 2008-07-10 US disclosed
US-7335775-B2 Effector conjugates, process for their production and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2008-02-26 US disclosed
US-7335775-B2 Effector conjugates, process for their production and their pharmaceutical use SCHERING AKTIENGESELLSCHAFT (DE) 2008-02-26 US disclosed
US-20070088060-A1 New effector conjugates, process for their production and their pharmaceutical use BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-04-19 US disclosed
US-20070088060-A1 New effector conjugates, process for their production and their pharmaceutical use BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2007-04-19 US disclosed